BlossomHill Therapeutics, Inc.
BLSMHealthcare|Biotechnology|US
$13.50
+1.15 (+9.31%)
DCF Value
$3.85
Tangible Book / Share
$3.02
Cash / Share
$3.51
Financials
Financial Snapshot
Market Cap
$392.6M
Enterprise Value
$320.6M
Revenue (TTM)
—
Net Income (TTM)
—
Cash & Investments
—
Net Cash
—
Free Cash Flow (TTM)
—
Operating CF (TTM)
—
Debt/Equity
0.28
R&D Spending
R&D (2025)
$56.1M
R&D Intensity
—
R&D Growth vs Prior
+76.5%
| Metric | Trend | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | |
| R&D Expense | $31.8M | $56.1M | |
| SG&A | $4.6M | $7.9M |
Income Statement
| Metric | Trend | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | |
| R&D | $31.8M | $56.1M | |
| SG&A | $4.6M | $7.9M | |
| Operating Income | -$36.4M | -$64.0M | |
| Interest Expense | $0.00 | $0.00 | |
| Pretax Income | -$30.7M | -$60.6M | |
| Net Income | -$30.7M | -$60.6M | |
| EPS (Diluted) | -1.06 | -2.08 | |
| EBITDA | -$36.1M | -$63.6M | |
| Shares Out. (M) | 29.08 | 29.08 |
Balance Sheet
| Metric | Trend | 2024 | 2025 |
|---|---|---|---|
| Cash & Equivalents | $100.1M | $136.7M | |
| Short-Term Investments | $0.00 | $0.00 | |
| Total Current Assets | $104.2M | $138.8M | |
| Total Assets | $106.8M | $163.0M | |
| Total Current Liabilities | $6.8M | $15.5M | |
| Long-Term Debt | $0.00 | $0.00 | |
| Total Liabilities | $179.7M | $294.7M | |
| Stockholders' Equity | -$72.9M | -$131.7M | |
| Retained Earnings | -$74.5M | -$135.0M |
Cash Flow Statement
| Metric | Trend | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -$31.4M | -$46.9M | |
| Capital Expenditure | -$92.0K | -$1.1M | |
| Free Cash Flow | -$31.5M | -$48.0M | |
| Investing Cash Flow | -$92.0K | -$1.1M | |
| Financing Cash Flow | $17.6M | $84.5M | |
| Issuance of Stock | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | |
| Stock Based Comp. | $504.0K | $1.1M | |
| Net Change in Cash | -$13.9M | $36.5M |
Dilution Tracker
Shares Outstanding
29M
5-Year Share Growth
+0.0%
Stock Issuance (2025)
$0.00
| Metric | Trend | 2024 | 2025 |
|---|---|---|---|
| Shares Out. (M) | 29.08 | 29.08 | |
| Change vs Prior % | — | 0.0% | |
| Stock Issuance | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | |
| Stock Based Comp. | $504.0K | $1.1M |
Margins & Profitability
| Metric | Trend | 2024 | 2025 |
|---|---|---|---|
| ROE % | 42.1% | 46.0% | |
| ROA % | -28.7% | -37.2% | |
| ROIC % | -36.2% | -43.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2024 | 2025 |
|---|---|---|---|
| Revenue | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | |
| Operating Income | 0.0% | -75.9% | |
| Net Income | 0.0% | -97.3% | |
| EPS (Diluted) | 0.0% | -96.2% | |
| Operating Cash Flow | 0.0% | -49.4% | |
| Free Cash Flow | 0.0% | -52.3% | |
| R&D Expense | 0.0% | 76.5% | |
| SG&A Expense | 0.0% | 71.8% | |
| Total Assets | 0.0% | 52.6% | |
| Book Value / Share | 0.0% | -80.7% | |
| Debt | 0.0% | 4166.3% | |
| Diluted Shares | 0.0% | 0.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B4.47
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$3.85
Tangible Book / Share
$3.02
Net Current Assets / Share
$2.02
Graham Net-Net
$1.96
Cash / Share
$3.51
| Metric | Trend | 2024 | 2025 |
|---|---|---|---|
| P/E Ratio | -15.09 | -7.69 | |
| P/S Ratio | 0.00 | 0.00 | |
| P/B Ratio | -6.38 | -3.53 | |
| EV/EBITDA | -10.14 | -5.52 | |
| EV/Revenue | 0.00 | 0.00 |
Analyst Estimates & Quality
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$161.1M | -$98.3M | -$99.9M |
| EPS | $-5.54 | $-3.38 | $-3.49 |
| # Analysts (EPS) | 2 | 3 | 4 |